EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy

Pawel Dubiela iD, Paulina Szymanska-Rozek, Piotr Hasinski iD, Patryk Lipinski iD, Grazina Kleinotiene, Dorota Giersz iD, Anna Tylki-Szymanska iD

Biomolecules · 2024

DOI: 10.3390/biom14070842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Pawel Dubiela und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-089 Bialystok, Poland. Hauptthemen laut MEDLINE: Gaucher Disease, Enzyme Replacement Therapy, Glucosylceramidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Children's Memorial Health Institute and Medical Research Agency, Medical Research Agency (Poland).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the GBA1 gene, leading to β-glucocerebrosidase deficiency and glucosylceramide accumulation.

Methods

We analyzed short- and long-term dynamics of lyso-glucosylceramide (lyso-Gb1) in a large cohort of GD patients undergoing enzyme replacement therapy (ERT).

Results

Eight-years analysis of lyso-Gb1 revealed statistically insignificant variability in the biomarker across the years and relatively high individual variability in patients’ results. GD type 1 (GD1) patients exhibited higher variability compared to GD type 3 (GD3) patients (coefficients of variation: 34% and 23%, respectively; p-value = 0.0003). We also investigated the short-term response of the biomarker to enzyme replacement therapy (ERT), measuring lyso-Gb1 right before and 30 min after treatment administration. We tested 20 GD patients (16 GD1, 4 GD3) and observed a rapid and significant reduction in lyso-Gb1 levels (average decrease of 17%; p-value < 0.0001). This immediate response reaffirms the efficacy of ERT in reducing substrate accumulation in GD patients but, on the other hand, suggests the biomarker’s instability between the infusions.

Conclusions

These findings underscore lyso-Gb1’s potential as a reliable biomarker for monitoring efficacy of treatment. However, individual variability and dry blood spot (DBS) testing limitations urge a further refinement in clinical application. Our study contributes valuable insights into GD patient management, emphasizing the evolving role of biomarkers in personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseEnzyme Replacement TherapyGlucosylceramidaseHumansMaleFemaleAdultMiddle AgedAdolescentYoung AdultBiomarkersChildPsychosineAgedChild, Preschool

Stichwörter der Autor:innen

Gaucher diseasebiomarkerenzyme replacement therapyglucosylsphingosinelyso-Gb1

Substanzen

GlucosylceramidaseBiomarkersPsychosine

Autor:innen und Institutionen

  • Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-089 Bialystok, Poland.
  • Department of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria.
  • Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, 00-927 Warsaw, Poland.
  • Department of Internal Medicine and Gastroenterology, Municipal Hospital, 43-100 Tychy, Poland.
  • Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy, 00-136 Warsaw, Poland.
  • Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.

ORCID-Profile: Pawel Dubiela, Piotr Hasinski, Patryk Lipinski, Dorota Giersz, Anna Tylki-Szymanska

Förderung

  • The Children's Memorial Health Institute and Medical Research Agency
  • Medical Research Agency (Poland)

Zitieren

APA

Dubiela, P., Szymanska-Rozek, P., Hasinski, P., Lipinski, P., Kleinotiene, G., Giersz, D., & Tylki-Szymanska, A. (2024). Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy. Biomolecules. https://doi.org/10.3390/biom14070842

Vancouver

Dubiela P, Szymanska-Rozek P, Hasinski P, Lipinski P, Kleinotiene G, Giersz D, et al. Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy. Biomolecules. 2024. doi:10.3390/biom14070842

BibTeX
@article{Dubiela2024,
  author = {Dubiela, Pawel and Szymanska-Rozek, Paulina and Hasinski, Piotr and Lipinski, Patryk and Kleinotiene, Grazina and Giersz, Dorota and Tylki-Szymanska, Anna},
  title = {Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14070842}
}
Kostenlos starten →